- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Allowed claims are expected to cover novel methylone-inspired neuroplastogenic compounds for potential treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric”...
CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker,...
EB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial Reported preclinical...
With an addition to its website — a psychedelic resource page — it seems the FDA is increasingly interested in psychedelic drug development. But even with the growing regulatory interest,...
The Psychedelic Drugs resource page added to the FDA website might be yet another indicator that the regulator is increasingly interested in the field’s potential. In publishing this resource page,...
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003. The company aims to treat psychiatric and neurological disorders by preserving...
GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),...
FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),...
In this Q&A, Tucker explains what set Enveric apart from the first wave of psychedelic biotech companies: rather than rushing traditional molecules into the clinic, the team chose to do...
As clinical research advances beyond first-generation compounds, scientists are rethinking what psychedelic-inspired therapies could look like and how they may reshape the future of mental healthcare. Full Article >>